Advances in understanding psoriasis pathophysiology have led to a variety of anti-psoriatic therapies, including small molecules and biologic agents. Current and emerging agents may confer improved disease management as well as the potential to reduce associated comorbidities compared with traditional systemic treatments. Thus, the need to define treatment goals and to measure treatment outcomes by means of parameters of clinical severity and quality of life has intensified. This session will discuss the underlying immunologic interaction and signaling mechanisms in psoriatic diseases as a foundation for the latest targeted treatments (e.g., mechanisms underlying itch, the role of inflammation in psoriatic and cardiovascular disease, mechanisms of rapid therapeutic response); the latest data surrounding available and emerging PsO treatments; and their impact on common comorbidities. Factors such as safety and efficacy, quality of life, patient self-perception, and adherence that can help clinicians differentiate among available treatment options will be explored. Lastly, key learnings will be applied by integrating individual patient needs, existing comorbidities, patient preferences, and available targeted and biologic agents into individualized treatment plans.